{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:39:20Z","timestamp":1790368760465,"version":"4.1.0"},"reference-count":50,"publisher":"Informa UK Limited","issue":"3","funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NCT01965353"],"award-info":[{"award-number":["NCT01965353"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2017,3,4]]},"DOI":"10.1080\/17474086.2017.1280388","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T22:08:02Z","timestamp":1484172482000},"page":"229-237","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Deacetylase inhibitors: an advance in myeloma therapy?"],"prefix":"10.1080","volume":"10","author":[{"given":"Jacob P.","family":"Laubach","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus F.","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cl\u00ednica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Irmandade da Santa Casa de Misericordia de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Changzheng Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital of Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Gachon University Gil Medical Center, Incheon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,2]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71125-8"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.11.007"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0433"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-665018"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1671"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.4161\/15592294.2014.983367"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.392"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-487884"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011483"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0530"},{"issue":"21","key":"CIT0015","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood.V124.21.2120.2120","volume":"124","author":"Richardson PG","year":"2014","journal-title":"Blood"},{"issue":"7","key":"CIT0016","first-page":"3071","volume":"61","author":"Hideshima T","year":"2001","journal-title":"Cancer Res"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1334037100"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3531"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016055"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00939-5"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503221102"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.015495"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235663"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12388"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2536759100"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2009.02.019"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701817258"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.661175"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.7068"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-481325"},{"key":"CIT0032","doi-asserted-by":"crossref","unstructured":"Richardson PG, Schlossman RL, Alsina M, et al. Time to event analyses in PANORAMA 2: a phase 2 study of panobinostat, bortezomib, and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma. Blood. 2013;122:1970.\u200b","DOI":"10.1182\/blood-2013-01-481325"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1173"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-318055"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.262"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2016.1096773"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294983"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-suppl_1-10"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2014.02.001"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"CIT0041","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Gregory TB, Faber EA, et al. A phase I\/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (MM): comparison of two expansion cohorts. Blood. 2015;126:1825.\u200b","DOI":"10.1200\/jco.2015.33.15_suppl.8513"},{"key":"CIT0042","doi-asserted-by":"crossref","unstructured":"Shah JJ, Thomas SK, Weber DM, et al. Phase 1\/1b study of the efficacy and safety of the combination of panobinostat + carfilzomib in patients with relapsed and\/or refractory multiple myeloma. \u00a0Blood. 2012;120:4081.\u200b","DOI":"10.1182\/blood.V120.21.4081.4081"},{"issue":"21","key":"CIT0043","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood.V124.21.32.32","volume":"124","author":"Kaufman JL","year":"2014","journal-title":"Blood"},{"key":"CIT0044","doi-asserted-by":"crossref","unstructured":"Reu F, Valent J, Malek E, et al. A phase I study of ixazomib in combination with panobinostat and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2015;126:4221. \u200b","DOI":"10.1182\/blood.V126.23.4221.4221"},{"key":"CIT0045","doi-asserted-by":"crossref","unstructured":"Chari A, Cho H, Leng S, et al. A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. \u00a0Blood. 2015;126:4226.\u200b","DOI":"10.1182\/blood.V126.23.4226.4226"},{"key":"CIT0046","doi-asserted-by":"crossref","unstructured":"Raje N, Hari PN, Vogl DT, et al. Rocilinostat (ACY-1215), a selective HDAC6 inhibitor, alone and in combination with bortezomib in multiple myeloma: preliminary results from the first-in-humans phase I\/II study. Blood. 2012;120:4061.\u200b","DOI":"10.1182\/blood.V120.21.4061.4061"},{"key":"CIT0047","doi-asserted-by":"crossref","unstructured":"Vogl D, Raje N, Hari P, et al. Phase 1B results of ricolinostat (ACY-1215) combination therapy with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (MM). Blood. 2014;124:4764. \u200b","DOI":"10.1182\/blood.V124.21.4764.4764"},{"key":"CIT0048","doi-asserted-by":"crossref","unstructured":"Yee A, Bensinger W, Voorhees P, et al. Ricolinostat (ACY-1215), the first selective HDAC6 inhibitor, in combonation with lenalidomide and dexamethasone in patients with relapsed and relapsed-and-refractory multiple myeloma: phase 1b results (ACE-MM-101 study). Blood. 2015;126:3055.\u200b","DOI":"10.1182\/blood.V126.23.3055.3055"},{"key":"CIT0049","doi-asserted-by":"crossref","unstructured":"Raje N, Bensinger W, Cole C, et al. Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study). Blood. 2015;126:4228.\u200b","DOI":"10.1182\/blood.V126.23.4228.4228"},{"key":"CIT0050","doi-asserted-by":"crossref","unstructured":"Shah JJ, Feng L, Manasanch EE, et al. Phase I\/II trial of the efficacy and safety of combination therapy with lenalidomide\/bortezomib\/dexamethasone (RVD) and panobinostat in transplant-eligible patients with newly diagnosed multiple myeloma. Blood. 2015;126:187.\u200b","DOI":"10.1182\/blood.V126.23.187.187"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2017.1280388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T22:19:02Z","timestamp":1601331542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2017.1280388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,2,17]]},"published-print":{"date-parts":[[2017,3,4]]}},"alternative-id":["10.1080\/17474086.2017.1280388"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2017.1280388","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}